Scarica l'app Stockscreener
23.46
0.09%
0.02
Dopo l'orario di chiusura:
23.43
-0.03
-0.13%
Panoramica
Notizia
Cronologia dei prezzi
Catena di opzioni
Financials
Perché ASRT Giù?
Forum
Previsione
Frazionamento azionario
Precedente Chiudi:
$23.44
Aprire:
$23.44
Volume 24 ore:
233.33K
Relative Volume:
0.87
Capitalizzazione di mercato:
$151.60M
Reddito:
$118.71M
Utile/perdita netta:
$-30.38M
Rapporto P/E:
-7.9701
EPS:
-2.9435
Flusso di cassa netto:
$-28.18M
1 W Prestazione:
+0.21%
1M Prestazione:
+30.04%
6M Prestazione:
+116.29%
1 anno Prestazione:
+122.48%
Intervallo 1D:
$23.42
$23.46
Intervallo di 1 settimana:
$23.36
$23.46
Portata 52W:
$8.61
$23.46
Assertio Holdings Inc Stock (ASRT) Company Profile
Nome
Assertio Holdings Inc
Settore
Telefono
(224) 419-7106
Indirizzo
100 S. SAUNDERS ROAD, LAKE FOREST, IL
Compare ASRT vs TAK, HLN, TEVA, ZTS, UTHR
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
ASRT
Assertio Holdings Inc
|
23.46 | 151.47M | 118.71M | -30.38M | -28.18M | -2.9435 |
TAK
Takeda Pharmaceutical Co Adr
|
15.87 | 51.34B | 29.91B | 1.30B | 3.49B | 0.4056 |
HLN
Haleon Plc Adr
|
9.24 | 41.15B | 14.54B | 2.22B | 2.58B | 0.4871 |
TEVA
Teva Pharmaceutical Industries Ltd Adr
|
34.61 | 39.67B | 17.53B | 1.58B | 444.18M | 1.3457 |
ZTS
Zoetis Inc
|
80.23 | 34.09B | 9.51B | 2.64B | 2.14B | 6.0361 |
UTHR
United Therapeutics Corp
|
578.43 | 24.13B | 3.17B | 1.29B | 1.01B | 27.09 |
Assertio Holdings Inc Stock (ASRT) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2026-04-09 | Downgrade | H.C. Wainwright | Buy → Neutral |
| 2024-07-26 | Iniziato | Maxim Group | Buy |
| 2024-07-03 | Iniziato | H.C. Wainwright | Buy |
| 2022-11-07 | Iniziato | Lake Street | Buy |
| 2018-11-30 | Downgrade | Mizuho | Buy → Neutral |
Assertio Holdings Inc Borsa (ASRT) Ultime notizie
Ocugen, Assertio among healthcare stocks set to join Russell Microcap; Definium Therapeutics, Tvardi Therapeutics to exit - MSN
Assertio Announces Amended And Restated Merger Agreement With Garda Therapeutics >ASRT - Moomoo
Assertio Deadline Alert - TMX Newsfile
$HAREHOLDER ALERT: The M&A Class Action Continues to Investigate the Merger-ASRT, SILA, KW, and UNF - The Malaysian Reserve
ASRT Stock Price, Quote & Chart | ASSERTIO HOLDINGS INC (NASDAQ:ASRT) - ChartMill
Assertio gets sweetened $153M buyout offer from Garda Therapeutics - MSN
Zydus buys Assertio for $166 million to deepen US specialty and oncology presence - MSN
Assertio Investor Alert: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Assertio Holdings, Inc.ASRT - Business Wire
Are SEM, UNF, CNTA, ASRT Obtaining Fair Deals for their Shareholders? - Sahm
Zydus offers $23.50 cash per share to buy Assertio (ASRT) — Board backs deal - Stock Titan
Zydus (NASDAQ: ASRT) offers $23.50 per share in cash tender for Assertio - Stock Titan
Assertio Therapeutics to be acquired by Zydus Worldwide - TipRanks
Assertio Holdings to be acquired by Zydus Worldwide in $23.50 per share cash deal - Investing.com Australia
Assertio Holdings, Inc. Announces Pre-Commencement Issuer Tender Offer and Merger Update – SEC Form 8-K Filing May 18, 2026 - Minichart
Assertio to be acquired in $23.50/share cash tender offer by Zydus - TradingView
Assertio (ASRT) to be acquired for $23.50 per share; tender offer starts May 18, 2026 - Stock Titan
Assertio (ASRT) moves 17.0% higher: Will this strength last? - MSN
Assertio's Acquisition: What's the Deal and Why Now - Kavout
Zydus Expands US Cancer Drug Business with Assertio Acquisition - Chemical Industry Digest
Director of Assertio (NASDAQ: ASRT) makes 13,332-share stock gift - Stock Titan
Assertio Holdings (ASRT) price target decreased by 12.42% to 24.34 - MSN
Zydus-Assertio Deal: US Revenue Might Peak In 2029 But Rolvedon Promises More - Citeline News & Insights
symbol__ Stock Quote Price and Forecast - CNN
Zydus Lifesciences Buys Assertio In US To Strengthen Cancer Treatment Push - Siliconindia
Zydus to Acquire US Oncology Pharma Firm Assertio in USD 166 Million Deal - Medical Dialogues
Zydus (ASRT) proposes $23.50 cash tender offer; Schedule TO forthcoming - Stock Titan
Zydus to acquire Assertio in $166m deal - Yahoo Finance
Zydus Life spurts as board to mull share buyback; arm signs deal to acquire Assertio - Business Standard
Zydus to acquire US firm Assertio for $166.4 million - Ahmedabad Mirror
Buyback and Acquisition Announcement: This pharma company shares BIG update for shareholders - Zee Business
Zydus Lifesciences shares jump 6% on buyback buzz; co announces $166 mn Assertio acquisition - The Economic Times
Zydus Lifesciences acquires Assertio in ₹1,570 crore US expansion push - domain-b.com
Zydus Worldwide DMCC to Acquire Entire Stake in Assertio Holdings for USD 166.4 Million - scanx.trade
Zydus to acquire US-based Assertio for $166.4 million - The Indian Express
Zydus to acquire US-based Assertio for $166.4 M to support oncology therapies - BioSpectrum India
Zydus Lifesciences arm to acquire US oncology firm Assertio - VCCircle
Zydus to buy Assertio for $166.4 million - The Economic Times
Zydus to acquire Assertio in all-cash tender offer - Express Pharma
Zydus Lifesciences to acquire Assertio for USD 166.4 mn - ET BrandEquity
Zydus and Assertio Holdings enter into an agreement for Zydus to acquire Assertio in an all-cash tender offer - IndiaMedToday
Zydus Lifesciences to Acquire Assertio for $166.4 Million - outlookbusiness.com
Zydus buys US specialty drugmaker Assertio in Rs 1,600 crore all-cash deal - TradingView
Zydus Lifesciences arm to acquire U.S. oncology firm Assertio for $166 million - The Hindu
ASRT | Assertio Holdings, Inc. Common FinancialsIncome Statement - Quiver Quantitative
Assertio Holdings Inc Azioni (ASRT) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
Assertio Holdings Inc Azioni (ASRT) insider trading
| Commercio interno | Relazione | Data | Transazione | Costo | #Azioni | Valore ($) | #Azioni Totale |
|---|---|---|---|---|---|---|---|
| Patel Ajay | EVP and CFO |
Feb 21 '26 |
Option Exercise |
0.00 |
1,143 |
0 |
16,508 |
| Schwichtenberg Paul | President and COO |
Feb 21 '26 |
Option Exercise |
0.00 |
1,143 |
0 |
14,553 |
| Schlessinger Sam | EVP, General Counsel |
Feb 18 '26 |
Option Exercise |
0.00 |
2,778 |
0 |
15,344 |
| Schwichtenberg Paul | President and COO |
Feb 18 '26 |
Option Exercise |
0.00 |
2,778 |
0 |
14,787 |
| Patel Ajay | EVP and CFO |
Feb 18 '26 |
Option Exercise |
0.00 |
2,778 |
0 |
16,742 |
| Schlessinger Sam | EVP, General Counsel |
Feb 07 '26 |
Option Exercise |
0.00 |
1,389 |
0 |
13,185 |
| Schwichtenberg Paul | President and COO |
Feb 07 '26 |
Option Exercise |
0.00 |
1,666 |
0 |
12,834 |
| Patel Ajay | EVP and CFO |
Feb 07 '26 |
Option Exercise |
0.00 |
1,666 |
0 |
14,789 |
| Stark David Matthew | Director |
Nov 10 '25 |
Sale |
0.76 |
8,959 |
6,806 |
98,541 |
5.02%
5.78%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):